Journal of Diabetes Science and Technology
Volume 5, Issue 5, September 2011

ORIGINAL ARTICLE

A Pan-European and Canadian Prospective Survey to Evaluate Patient Satisfaction with the SoloSTAR Insulin Injection Device in Type 1 and Type 2 Diabetes

Nicolae Hancu, M.D., Ph.D.,[1] Leszek Czupryniak, Ph.D.,[2] Elisabeth Genestin, M.D.,[3] and Harald Sourij, M.D.[4]

Abstract

Objective:

This study evaluated patient satisfaction with SoloSTAR® (sanofi-aventis), a prefilled insulin pen device for injection of insulin glargine or insulin glulisine.

Methods:

This was a 6–8-week multicenter (n = 652), observational, prospective Pan-European and Canadian registry study in patients with diabetes mellitus (n = 6542) who recently switched to or started treatment with insulin glargine and/or insulin glulisine using SoloSTAR or were insulin naïve. At the baseline visit, patients were asked to evaluate their satisfaction with their previous device, if applicable. After 6–8 weeks of SoloSTAR use, patients were asked to rate their satisfaction.

Results:

Overall, 6481 patients (mean age 54 years, 48.7% male, 72% type 2 diabetes) were analyzed in this study. Of these, 4995 (77.1%) patients had used insulin before the study and 1641 (32.9%) and 3395 (68.0%) patients had previously used prefilled and/or reusable pens, respectively. During the study, SoloSTAR was used to administer insulin glargine and/or insulin glulisine by 97.3% and 36.0% of patients, respectively (both: 27.0%). Most patients rated SoloSTAR as "excellent/good" for ease of use (97.9%), learning to use (98.3%), selecting the dose (97.6%), and reading the dose (95.1%). Most patients rated ease of use (88.4%) and injecting a dose (84.5%) with SoloSTAR as "much easier/easier" versus their previous pen. Overall, 98% planned to continue using SoloSTAR. No safety concerns were reported.

Conclusion:

This European and Canadian survey shows that SoloSTAR was well accepted in this large patient population. Most patients preferred SoloSTAR to their previous pen and planned to continue SoloSTAR use.

J Diabetes Sci Technol 2011;5(5):1224-1234

Author Affiliations: [1]University of Medicine, Cluj-Napoca, Romania; [2]Diabetology and Metabolic Diseases Department, Medical University of Lodz, Lodz, Poland; [3]sanofi-aventis, Paris, France; and [4]Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria

Abbreviations: (SD) standard deviation, (T1DM) type 1 diabetes mellitus, (T2DM) type 2 diabetes mellitus, (TEAE) treatment-emergent adverse event

Keywords: European, insulin glargine, insulin glulisine, insulin pen device, patient satisfaction, SoloSTAR

Corresponding Author: Nicolae Hancu, M.D., Ph.D., Clinicilor Street no 2-4, 400006 Cluj Napoca, Romania; email address nhancu@umfcluj.ro